{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:08:30Z","timestamp":1759410510122},"reference-count":28,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"name":"Shionogi & Co., Ltd."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.03.072","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T18:18:25Z","timestamp":1396981105000},"page":"3004-3009","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets"],"prefix":"10.1016","volume":"32","author":[{"given":"Motoyasu","family":"Onishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cevayir","family":"Coban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.vaccine.2014.03.072_bib0005","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0020-7519(02)00193-5","article-title":"Theories on malarial pigment formation and quinoline action","volume":"32","author":"Sullivan","year":"2002","journal-title":"Int J Parasitol"},{"issue":"5","key":"10.1016\/j.vaccine.2014.03.072_bib0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/00034983.1997.11813168","article-title":"Malarial pigment (haemozoin): a very active \u2018inert\u2019 substance","volume":"91","author":"Arese","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.072_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1084\/jem.20041836","article-title":"Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin","volume":"201","author":"Coban","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.072_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.chom.2009.12.003","article-title":"Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9","volume":"7","author":"Coban","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.072_bib0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4161\/hv.22950","article-title":"TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36\/AHG malaria vaccine in nonhuman primate models","volume":"9","author":"Tougan","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.072_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines","volume":"59","author":"Cox","year":"2004","journal-title":"Scand J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.03.072_bib0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","article-title":"Antibody response to influenza vaccination in the elderly: a quantitative review","volume":"24","author":"Goodwin","year":"2006","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2014.03.072_bib0040","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.vaccine.2012.10.007","article-title":"Adjuvants in influenza vaccines","volume":"30","author":"Tetsutani","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.072_bib0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxlet.2011.03.001","article-title":"Progress in understanding adjuvant immunotoxicity mechanisms","volume":"203","author":"Batista-Duharte","year":"2011","journal-title":"Toxicol Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2014.03.072_bib0050","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1128\/AAC.47.12.3846-3852.2003","article-title":"Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults","volume":"47","author":"Sauder","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"37","key":"10.1016\/j.vaccine.2014.03.072_bib0055","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1016\/j.vaccine.2005.04.042","article-title":"Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography","volume":"23","author":"Tanimoto","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.072_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2332\/allergolint.10-RAI-0194","article-title":"The malarial metabolite hemozoin and its potential use as a vaccine adjuvant","volume":"59","author":"Coban","year":"2010","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.vaccine.2014.03.072_bib0065","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/14760584.6.5.659","article-title":"MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations","volume":"6","author":"Puig Barbera","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"11","key":"10.1016\/j.vaccine.2014.03.072_bib0070","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00412-11","article-title":"Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques","volume":"55","author":"Kitano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.vaccine.2014.03.072_bib0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.immuni.2011.03.019","article-title":"Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms","volume":"34","author":"Kuroda","year":"2011","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.072_bib0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4161\/hv.18445","article-title":"Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults","volume":"8","author":"Della Cioppa","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2014.03.072_bib0085","series-title":"Sixth Vaccine & ISV Annual Global Congress","article-title":"Pyrogenicity evaluation of influenza vaccine with TLR agonists in ferret","author":"Kitano","year":"2012"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2014.03.072_bib0090","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1099\/0022-1317-73-6-1345","article-title":"Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins","volume":"73","author":"Pickering","year":"1992","journal-title":"J Gen Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2014.03.072_bib0095","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMra1002842","article-title":"Influenza vaccines for the future","volume":"363","author":"Lambert","year":"2010","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.vaccine.2014.03.072_bib0100","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1016\/j.vaccine.2007.08.042","article-title":"Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects","volume":"25","author":"Couch","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.072_bib0105","first-page":"2","article-title":"The ferret model for influenza","author":"Matsuoka","year":"2009","journal-title":"Curr Protoc Microbiol"},{"issue":"19","key":"10.1016\/j.vaccine.2014.03.072_bib0110","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","article-title":"Vaccine adjuvants revisited","volume":"25","author":"Aguilar","year":"2007","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2014.03.072_bib0115","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1016\/j.vaccine.2010.10.009","article-title":"Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults","volume":"28","author":"Treanor","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.03.072_bib0120","doi-asserted-by":"crossref","first-page":"e1000559","DOI":"10.1371\/journal.ppat.1000559","article-title":"Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases","volume":"5","author":"Shio","year":"2009","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.vaccine.2014.03.072_bib0125","doi-asserted-by":"crossref","first-page":"e6510","DOI":"10.1371\/journal.pone.0006510","article-title":"Malarial hemozoin is a Nalp3 inflammasome activating danger signal","volume":"4","author":"Dostert","year":"2009","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.vaccine.2014.03.072_bib0130","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.072_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/08830185.2013.773326","article-title":"Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects","volume":"32","author":"Kuroda","year":"2013","journal-title":"Int Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.072_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T05:13:55Z","timestamp":1572326035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14004538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":28,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14004538"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}